Core Laboratories Inc

CLB is in a Stage 4 decline but is mean-reversion eligible, warranting a tactical bullish stance. The post-capitulation pattern and extreme oversold context signal supply exhaustion and potential stabilization around the washout low, and short-term price action shows a strong recovery bar with volume confirming initial acceptance, supporting immediate participation on this rebound.

• ↑Earnings yield ~0.77 signals undervaluation relative to earnings potential.
• ↑Q1 2026 buybacks: 51,000 shares (~$900k), sixth straight quarter.
• ↓Q1 revenue $121.8m down 12% sequentially and down 1% YoY.